CAJ | 학술논문

　　目的观察聚乙二醇化干扰素（Peg-IFN）-α2a治疗慢性丙型肝炎（CHC）并发甲状腺疾病患者的效果及安全性。方法选择CHC患者56例，均未并发肝硬化，其中28例并发甲状腺疾病为A组，28例无甲状腺疾病为B组，均接受Peg-IFN-α2a联合利巴韦林治疗，分别于治疗4周、12周、48周及随访24周时评价疗效，并观察两组患者肝功能及甲状腺功能变化情况。Peg-IFN-α2a治疗中，A组给予抗甲状腺药物或左甲状腺素片替代治疗，B组出现甲状腺功能异常时给予严密监测，必要治疗甲状腺疾病，均完成抗病毒治疗。结果治疗48周，A组病毒学应答率为92.8%，B组为96.4%；A组持续病毒应答率为89.2%，B组为92.8%，两组均具有良好疗效，差异无统计学意义（P均＞0.05）。两组患者肝功能均随抗丙型肝炎病毒治疗而好转。结论 Peg-IFN-α2a联合利巴韦林治疗CHC并发甲状腺疾病是安全、有效的。
　　목적관찰취을이순화간우소（Peg-IFN）-α2a치료만성병형간염（CHC）병발갑상선질병환자적효과급안전성。방법선택CHC환자56례，균미병발간경화，기중28례병발갑상선질병위A조，28례무갑상선질병위B조，균접수Peg-IFN-α2a연합리파위림치료，분별우치료4주、12주、48주급수방24주시평개료효，병관찰량조환자간공능급갑상선공능변화정황。Peg-IFN-α2a치료중，A조급여항갑상선약물혹좌갑상선소편체대치료，B조출현갑상선공능이상시급여엄밀감측，필요치료갑상선질병，균완성항병독치료。결과치료48주，A조병독학응답솔위92.8%，B조위96.4%；A조지속병독응답솔위89.2%，B조위92.8%，량조균구유량호료효，차이무통계학의의（P균＞0.05）。량조환자간공능균수항병형간염병독치료이호전。결론 Peg-IFN-α2a연합리파위림치료CHC병발갑상선질병시안전、유효적。
Objective To observe the effect and safety of pegylated interferon for chronic hepatitis C (CHC) patients with thyroid dysfunction. Methods Total of 56 patients with CHC without liver cirrhosis were divided into complication thyroid disease of group A (28 cases) and without thyroid disease of group B (28 cases). Both groups were treated with Peg-IFN-α 2a and ribavirin. The evaluation of efficacy, liver function and thyroid function were analyzed at 4th week, 12th week, 48th week and the 24th week of follow-up, respectively. Results At 48th week, the virologic response rate of group A was 92.8% and of 96.4% for group B, the sustained viral response rates of group A was 89.2% and 92.8% for group B. There were no significant difference between two groups (P > 0.05). Liver function of both groups improved after anti-HCV therapy. Conclusions Peg-IFN-α 2a combined with ribavirin in treatment of patients with CHC complicated with thyroid disease was safe and effective.